Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today provided an update on its lead clinical programs, ...

The CRISPR gene editing company will reduce its workforce by 27% over the course of the year as it discontinues a treatment for alpha-1 antitrypsin deficiency.

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, ...

Cambridge, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing ...

Graft-Versus-Host disease market Insights. DelveInsight's Graft-Versus-Host Disease Market report offers an in-depth understanding of the epidemiology and ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Analyst Cory Jubinville, PhD from LifeSci Capital maintained a Buy rating on Mereo Biopharma Group Plc (MREO – Research Report) and keeping the ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

4D Molecular Therapeutics is axing two clinical programs and cutting off funds for three other assets, with resources to be ...

Intellia Therapeutics Inc. is shedding employees and paring down its pipeline as it transforms from a late-stage development ...

Intellia Therapeutics (NTLA) stock falls, sending its gene editing rivals lower, as Wall Street reacts to its latest layoff ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...